The Use of Disopyramide in Resistant Cardiac Arrhythmias Due to Acute Ischaemic Heart Disease
- 1 September 1977
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 5 (5), 369-373
- https://doi.org/10.1177/030006057700500514
Abstract
Disopyramide, a new anti-arrhythmic drug, has been assessed in twenty-one episodes of cardiac arrhythmia secondary to acute ischaemic heart disease which failed to respond to more conventional suppressive therapy with lignocaine and other standard drugs. The intravenous administration of 100 mg of disopyramide resulted in suppression of two out of seven episodes of supraventricular arrhythmia, and eleven out of fourteen episodes of ventricular arrhythmias. Successful suppression correlated with blood levels of disopyramide in most cases of ventricular arrhythmias but not in the supraventricular arrhythmias. There were no adverse effects on blood pressure or cardiac function. There were minimal effects on conduction in the electrocardiogram. It is concluded that disopyramide, which probably acts by direct depression of myocardial irritability, is a useful new anti-arrhythmic drug in acute myocardial infarction, especially in those patients with ventricular arrhythmias resistant to more conventional anti-arrhythmic therapy.This publication has 8 references indexed in Scilit:
- Discussion of Papers Presented in Session IIJournal of International Medical Research, 1976
- Animal Studies — A Theoretical Basis for TreatmentJournal of International Medical Research, 1976
- Study of a New Analgesic Compound in the Treatment of Tension Headache*Journal of International Medical Research, 1976
- Electrophysiologic effects of disopyramide phosphate—A new antiarhythmic agentThe American Journal of Cardiology, 1973
- Lignocaine Therapy for Ventricular Ectopic Activity after Acute Myocardial Infarction: A Double-blind TrialBMJ, 1971
- Hospital registration in patients with acute myocardial infarctionAmerican Heart Journal, 1970
- FREE NORADRENALINE AND ADRENALINE EXCRETION IN RELATION TO THE DEVELOPMENT OF CARDIAC ARRHYTHMIAS AND HEART-FAILURE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1969
- PHARMACOLOGY OF A NEW ANTIARRHYTHMIC AGENT, GAMMA-DIISOPROPYLAMINO-ALPHA-PHENYL-ALPHA-(2-PYRIDYL)-BUTYRAMIDE (SC-7031)1962